Evercore Cuts Medtronic (NYSE:MDT) Price Target to $108.00

Medtronic (NYSE:MDT) had its target price lowered by Evercore from $115.00 to $108.00 in a research report report published on Monday,MarketScreener reports. The firm currently has an outperform rating on the medical technology company’s stock.

Several other analysts have also recently commented on the stock. Mizuho raised shares of Medtronic to a “strong-buy” rating in a research note on Wednesday, February 18th. Wells Fargo & Company began coverage on shares of Medtronic in a research note on Friday, January 30th. They issued an “overweight” rating and a $114.00 target price for the company. Leerink Partners reaffirmed an “outperform” rating and issued a $119.00 target price on shares of Medtronic in a research note on Tuesday, March 10th. Argus lowered their target price on shares of Medtronic from $125.00 to $115.00 and set a “buy” rating for the company in a research note on Monday. Finally, Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Medtronic in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $109.10.

Medtronic Stock Up 2.6%

MDT stock opened at $88.65 on Monday. The stock has a market capitalization of $113.81 billion, a P/E ratio of 24.69, a PEG ratio of 2.24 and a beta of 0.75. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.87 and a current ratio of 2.54. Medtronic has a one year low of $79.55 and a one year high of $106.33. The company has a 50 day moving average price of $93.66 and a two-hundred day moving average price of $96.07.

Medtronic (NYSE:MDT) last released its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 EPS for the quarter, topping the consensus estimate of $1.34 by $0.02. The firm had revenue of $9.02 billion during the quarter, compared to analysts’ expectations of $8.89 billion. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. Medtronic’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same period in the previous year, the company earned $1.38 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, sell-side analysts expect that Medtronic will post 5.46 EPS for the current year.

Medtronic Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 17th. Stockholders of record on Friday, March 27th will be paid a dividend of $0.71 per share. The ex-dividend date of this dividend is Friday, March 27th. This represents a $2.84 annualized dividend and a dividend yield of 3.2%. Medtronic’s payout ratio is currently 79.11%.

Insider Activity

In other news, EVP Harry Skip Kiil sold 52,524 shares of the business’s stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the completion of the sale, the executive vice president directly owned 32,768 shares of the company’s stock, valued at $3,201,761.28. The trade was a 61.58% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.26% of the stock is owned by corporate insiders.

Institutional Trading of Medtronic

Institutional investors have recently made changes to their positions in the stock. Monetary Solutions Ltd purchased a new stake in shares of Medtronic during the 4th quarter valued at $27,000. Corundum Trust Company INC purchased a new stake in shares of Medtronic during the 3rd quarter valued at $27,000. Lodestone Wealth Management LLC purchased a new stake in shares of Medtronic during the 4th quarter valued at $27,000. Anfield Capital Management LLC lifted its holdings in shares of Medtronic by 410.7% during the 4th quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company’s stock valued at $27,000 after acquiring an additional 230 shares in the last quarter. Finally, Board of the Pension Protection Fund acquired a new position in shares of Medtronic during the 4th quarter valued at $29,000. 82.06% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: FDA clearance expands robotic/surgical addressable market — Medtronic received U.S. FDA clearance for its AI-enabled Stealth AXiS system for cranial and ENT procedures, extending the platform beyond spine and broadening opportunities in computer-assisted and robotic surgery. This is a clear product-side growth catalyst for surgical robotics and navigation adoption. Assessing Medtronic Valuation After Stealth AXiS FDA Clearance
• Positive Sentiment: Market tailwinds in core device markets — industry reports highlight multi-year growth in anesthesia/respiratory and lung-cancer surgery markets, with Medtronic named among leading vendors; these secular trends support steady revenue opportunities for MDT’s device franchises. Anesthesia & Respiratory Market Report Lung Cancer Surgery Market
• Neutral Sentiment: Investor note and price action coverage — market write-ups (e.g., Zacks) point to MDT’s intraday move and recent momentum; useful for short-term sentiment tracking but largely descriptive. Zacks: What Investors Need to Know
• Neutral Sentiment: Mixed analyst adjustments — several firms trimmed price targets (Evercore, Citi, others) but mostly kept positive/neutral ratings (buy/outperform/hold). That leaves medium-term upside in some models but increases short-term uncertainty. Evercore PT Adjustment Citi PT Adjustment
• Negative Sentiment: Stifel trims target citing MiniMed IPO impacts — Stifel cut its price target to $95 and flagged transaction-related effects from the recent MiniMed IPO as a reason for lowering near-term expectations; that raises near-term analyst-model risk and may weigh on sentiment. Stifel Cuts MDT Target to $95
• Negative Sentiment: Competitive pressure in cardiac rhythm devices — Johnson & Johnson launched an enhanced pulsed-field ablation device in Europe, signaling faster product rollouts from competitors in electrophysiology that could pressure share gains in select cardiac franchises. J&J launches enhanced PFA device

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).